Regensburg, Germany, December 4, 2013 / B3C newswire / – Lophius Biosciences GmbH, a privately held biotech company developing and marketing innovative T cell-based diagnostic systems for the early diagnosis and immunomonitoring, today announced that Dr. Robert Phelps has joined the Company as Director Business Operations.
Dr. Phelps has more than thirteen years successful international experiences in business development and licensing in the biotech and pharma industry. Lastly, he has been Head of Business Development & Licensing at SuppreMol GmbH in Munich, where he was responsible for all business development and licensing activities relating to the company’s clinical drug development candidates. Previous to that, he has held business development and licensing positions at various biotechnology and pharmaceutical companies. Dr. Phelps received his PhD in biochemistry from the University of Frankfurt and the Paul-Ehrlich-Institut in Germany, held a research position as a post-doctoral fellow at the Medical University of South Carolina, Charleston (SC), USA, and holds the Certified Licensing Professional (CLP) credentials.
"With his longstanding experience in business development and licensing, we are happy that we were able to get Robert on board" said Prof. Ralf Wagner, Managing Director of Lophius Biosciences. “He is a valuable addition to our team and will be instrumental in supporting our efforts to exploit the excellent development and marketing opportunities for our T cell-based diagnostic systems such as T-Track® CMV."
"I am very happy to join Lophius," Dr. Phelps added. "The Company has been highly successful in transforming their T cell monitoring platform technologies into viable products enabling doctors to individually adjust prophylactic and immunosuppressive therapy e.g. during solid organ and bone marrow transplantation to the benefit of patients. I am extremely impressed by the potential of their platform technologies and their deep product pipeline.”
About Lophius Biosciences
Lophius Biosciences GmbH, a German biotech company, is focusing on the development and marketing of innovative T-cell based diagnostic systems for diagnosis and immunomonitoring. The Company’s first product is T-Track® CMV, a diagnostic system intended to determine the functionality of the cell-mediated immune response in cytomegalovirus (CMV) seropositive transplant patients who undergo a immunosuppressive therapy. With its innovative products, the Company aims to significantly improve therapy control and personalized treatment of patients in the area of transplantation medicine, infectious and autoimmune diseases.
Dr. Robert Phelps
Director Business Operations
Lophius Biosciences GmbH
Tel: +49 (0)941 6309197-80